glp 1 eye issues GLP-1 Drugs and Ocular Disease: Between Neuroprotection and Risk GLP-1 Meds Reduce Risk of

GLP-1 is a hormone produced in the intestines in response to food intake

At 1 year after cessation, an estimated 40.2% of the on-treatment weight loss remained

Our GLP-1 Edge box is a 4-day supply of breakfast, lunch, dinner and snacks to give you an edge reaching your best self

Earlier initiation is reshaping patient journeys: Patients are starting GLP1 therapy within weeks of diagnosis, underscoring the need for streamlined access pathways and payer alignment to reduce delays, especially in Medicare populations

A new study explores how the meds affect mealtimes.

GLP-1GIPlanifibranor, a single-molecule agonist of GLP-1R, GIPR, PPAR, PPAR and PPAR, shows promising therapeutic efficacy against obesity-linked metabolic dysfunction in vitro and in mouse models via synergistic incretin and PPAR activity.